Drug major Lupin today said it has launched Solosec, an oral antibiotic used in treating bacterial vaginosis (BV) in women, in the US market.
The company has launched Solosec oral granules in the American market after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement.
With more than four million women treated for BV in the US annually, and only 50 per cent completing 5 to 7 day treatments, there is a clear need for an effective, single-dose oral treatment, Lupin Chief Executive Officer Vinita Gupta said in a statement.
According to the company, it only takes one packet of Solosec to complete treatment and the single dose stays in the body and continues to treat BV for four days without an alcohol restriction.
Solosec does not inhibit the enzyme that metabolises alcohol, it added.
Shares of Lupin were trading 0.60 per cent down at Rs 773.55 on the BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)